米力农对肺动脉高压的治疗作用及其机制探究-东南大学学报医学版

米力农对肺动脉高压的治疗作用及其机制探究

单位：1. 河北省承德医学院附属医院心脏外科, 河北承德 067000;
2. 河北省承德医学院附属医院 ICU, 河北承德 067000

分类号：R543.2

出版年·卷·期（页码）：2018·37·第一期（83-86）

摘要：

目的：观察不同剂量米力农对肺动脉高压患者的治疗作用，在此基础上探讨米力农的降低肺动脉高压的机制。方法：测定患者给药后平均体动脉压、肺动脉压、肺血管阻力、血清中肾素、血管紧张素、醛固酮水平和6分钟步行步数等指标。结果：与对照组相比3组患者肺动脉压力、平均体动脉压、肺血管阻力显著降低（P<0.01或0.05），同时能够显著性的提高6分钟步行步数（P<0.01或0.05）。高剂量组要明显优于中剂量组和低剂量组。3组给药组均能明显降低患者血清中肾素、血管紧张素Ⅱ、醛固酮水平，差异具有统计学意义（P<0.01或0.05）。结论：米力农能较好的缓解肺动脉高压，提高患者的肺功能。本研究为米力农的相关机制研究和临床实践提供了重要参考。

Objective: To study the different doses effect of milrinone to the treatment of patients with pulmonary artery hypertension. Based on this, the mechanism of milrinone to pulmonary artery hypertension have been discussed. Methods: Mean arterial pressure, pulmonary artery pressure, pulmonary ascular resistance, serum renin, angiotensin and aldosterone levels and 6 minutes walk steps were detected after and before the treatment. Results: Compared with control group, pulmonary arterial pressure, mean arterial pressure, pulmonary vascular resistance in the patients of the three groups decreased significantly(P<0.01 or 0.05), and significantly improve steps of 6-minutes walk(P<0.01 or 0.01). The results in the high dose group was better than those middle dose group and low dose group. In terms of reducing serum renin, angiotensin Ⅱ, aldosterone levels with statistically significant difference(P<0.01 or 0.01). Conclusion: Milrinone can alleviate pulmonary hypertension, improve the patients' lung function.This study for milrinone can make a example for mechanism research and clinical practice.

参考文献：

[1] CHEMLA D,HUMBERT M,SITBON O,et al.Systolic and mean pulmonary artery pressures:are they interchangeable in patients with pulmonary hypertension?[J].Chest,2015,147(4):943-950.
[2] 刘璐.雾化吸入磷酸二酯酶3抑制剂-米力农对合并肺动脉高压的慢性阻塞性疾病患者的临床观察[D].昆明医科大学,2014.
[3] HARALDSSON S A,KIELER-JENSEN N,RICKSTEN S E.The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension[J].Anesth Analg,2001,93(6):1439.
[4] GESSLER P,KACHEL W.Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension[J].Crit Care Med,2000,28(3):795-799.
[5] 赵向东,陆龙,崔振田.前列腺素E与米力农对室间隔缺损合并肺动脉高压患儿术后疗效比较[J].疑难病杂志.2010(06):406-407.
[6] CAREV M,BULAT C,KARANOVIC N,et al.Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery[J].Coll Antropol,2010,34(3):1113-1117.
[7] AKTAŞ T,AKTAŞ F,Z Ö,et al.Does crimean-congo hemorrhagic fever cause a vasculitic reaction with pulmonary artery enlargement and acute pulmonary hypertension?[J].Lung,2016,194(5):1-6.
[8] LAKSHMINRUSIMHA S,KESZLER M.Persistent pulmonary hypertension of the newborn[J].NeoReviews,2015,16(12):e680.
[9] GÖSSL M,KANE G C,MAUERMANN W,et al.Pulmonary hypertension in patients undergoing transcatheter aortic valve replacement:discussion of the current evidence[J].Circ Cardiovasc Interv,2015,8(6):e2253.
[10] HAGA S,TSUCHIYA H,HIRAI T,et al.A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression[J].Exp Lung Res,2015,41(1):21-31.
[11] BEN-SHOSHAN J,ENTIN-MEER M,GUZNER-GUR H,et al.The cardiorenal syndrome:a mutual approach to concomitant cardiac and renal failure[J].Isr Med Assoc J,2012,14(9):570-576.
[12] NG T M,ACKERBAUER K A,HYDERI A F,et al.Comparative effects of nesiritide and nitroglycerin on renal function,and incidence of renal injury by traditional and RIFLE criteria in acute heart failure[J].J Cardiovasc Pharmacol Ther,2012,17(1):79-85.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录